 unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
ow
resum coverag ow pt recent
transact gilead provid galapago strong
partner drive broad pipelin build commerci
oper eu filgotinib drive near-term upsid
cash posit provid downsid protect
resum coverag ow galapago clinical-stag biotechnolog compani
focus discov develop small molecul therapeut
differenti mode action galapago seri proprietari
partner compound current develop across varieti indic
notabl inflammatori diseas support valid innov
pipelin gilead galapago recent final long-term global
collabor deal valu gilead pay
galapago cash along equiti invest gilead
ownership galapago stand gain varieti way immedi cash
inject enabl manag continu develop on-going
clinic pre-clin program along provid mean expand
compani proven target discoveri engin scientist
addit deal allow galapago leverag gilead core compet
aid manag effort deliv integr biopharma
organ abil effici commerci compound
demonstr success clinic exchang invest gilead
receiv opt-in right galapago program ex-eu along warrant
potenti increas equiti ownership galapago strateg
transact grow gilead mid-to-l stage pipelin inflammatori diseas
increas earli stage research engin origin full note term
deal found gilead press releas found
believ galapago well posit success follow transact
gilead addit immedi benefit associ
collabor galapago seri valu driver believ like
contribut short long-term upsid among near-term valu
driver notabl filgotinib galapago lead product candid
filgotinib highli select orally-administ inhibitor current
develop varieti inflammatori indic lead indic
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
includ rheumatoid arthriti ra ulcer colliti uc crohn diseas
cd notabl compar competitor xeljanz olumi believ
drug best class efficaci cleaner safeti profil file
accept eu ra on-track year us see continu
progress filgotinib key valuat driver model us
royalti ou profit-split filgotinib
proprietari partner program provid near-term catalyst
addit filgotinib galapago seri program partner
proprietari repres key valu driver compani summari
program along next key catalyst found
exhibit galapago program catalyst
upcom day toledo compound disclosur repres addit
catalyst addit asset galapago current develop
class drug known toledo compound class drug intend
address inflammatori diseas though method action yet
disclos manag emphas continu confid program
began expect initi data notabl toledo
mechan outperform mechan manag evalu
preclin studi ibd broadli galapago intend host
day could provid insight pipelin
risk reward posit skew result near-term catalyst cash
posit gilead transact increas cash current
market cap provid investor signific downsid protect posit
risk/reward skew regard pipelin continu view filgotinib coupl
continu pipelin execut key factor drive glpg higher
filgotinib ra ibd pipelin asset drive risk/reward
filgotinib ra ibd pipelin asset drive risk/reward
deriv pt discount cash flow analysi use
wacc cash flow forecast expir
filgotinib patent main driver filgotinib
filgotinib still major driver assum greater share ra ad
ipf pipelin asset gener signific sale assum po
adjust peak sale filgotinib ra uc
cd total filgotinib mileston payment
ad gener peak po adjust global sale
ipf gener peak po adjust global sale
oa gener peak po adjust global sale
filgotinib drive forecast strong contribut ad ipf
pipelin asset assum po adjust peak sale filgotinib
ra uc cd
total filgotinib mileston payment ad gener
peak po adjust global sale ipf gener peak
po adjust global sale oa gener peak po
adjust global sale
filgotinib pipelin asset fail manag continu invest
 assum cash-per-share valu
overweight galapago
believ filgotinib addit pipelin
asset differenti carv
market share competit
filgotinib differenti profil versu
oral competitor xeljanz
olumi believ best class
efficaci cleaner safeti profil
especi anemia across indic
model peak po adjust global sale
filgotinib
filgotinib potenti approv
key inflammatori indic beyond
rheumatoid arthriti includ crohn
spondyl psoriat arthriti
data pipelin asset ad
ipf oa
encourag enough us
incorpor probabl adjust estim
molecul valuat await
matur data
main driver advanc
filgotinib ra ibd along continu
progress ipf oa ad program
risk achiev price
take signific time phase ii safeti
profil may assur protect
unknown side-effect broader phase
approv risk regulatori approv
assur potenti failur
gain approv one geographi
commerci risk ra market
competit number market
agent along agent develop
filgotinib pipelin product may
detail galapago develop program
rheumatoid arthriti ra filgotinib current review ema eu
approv potenti treatment ra applic valid
regulatori agenc august year manag intend file nda
fda ra regulatori submiss filgotinib treatment ra
support finch dataset base timelin estim
commerci filgotinib eu filgotinib
lead indic estim peak ww royalties/profit share galapago
ulcer coliti uc data phiii select studi filgotinib uc
expect recruit complet interim futil analysi
perform independ data monitor committe dmc committe
recommend dose filgotinib includ phiii
stage trial indic differenti efficaci dose level model ww
peak filgotinib uc royalties/profit share galapago
crohn diseas cd expect data on-going phiii divers studi
filgotinib recruit expect finish assum base case
commerci model ww peak filgotinib cd royalties/profit share
galapago
sjogren syndrom readout proof-of-concept studi evalu filgotinib
sjogren syndrom expect given uncertainti surround indic
explicitli valu filgotinib cash flow associ sjogren
cutan lupu erythematosu cle addit proof-of-concept studi filgotinib
evalu cle parallel sjogren data expect
sjogren current ascrib materi valu indic
idiopath pulmonari fibrosi ipf autotaxin inhibitor
shown posit result preclin clinic evalu recruit phiii
isabela studi ipf progress ahead schedul
upcom interim futil analysi expect phiii isabela trial
expect use basi nda submiss eu base
factor assum commerci probabl success po
adjust global sale
atop dermat ad galapago current develop partnership
morphosi novarti manag initi phii gecko trial
evalu drug patient moder sever atop dermat
antibodi target cytokin thought implic dermal
inflamm though key mileston note manag initi
ethnobridg studi japan given phii natur trial appli
probabl success assum commerci lead us peak
sale estim
osteoarthr oa galapago develop partnership servier
compound disease-modifi osteoarthr drug dmoad candid target
enzym lead degrad cartilag down-
regul confirm pre-clin anim model drug met
pharmacokinet safeti endpoint phi trial data on-going phii roccella
trial initi june expect given early-stag natur drug
assum commerci probabl success po adjust
global sale
exhibit discount analysi usd thousand except per share
price target includ risk adjust peak revenu attribut
galapago deriv price target discount cash flow dcf
analysi use discount rate termin growth rate
valuat methodolog prefer use dcf analysi valu biotechnolog
compani believ dcf fulli captur up-front invest period well
long-term earn potenti galapago pipelin asset investor
look biotechnolog multipl basi price-to-earnings prefer dcf rigor
requir explicit assumpt long-term prospect compani
discount rate util discount rate galapago compani still
clinical-stag biotechnolog compani despit asset phiii coverag
util discount rate commerci compani rate compani
random phii data rate develop stage compani
termin growth rate model explicit revenu assum
termin growth rate onward
revenu includ risk-adjust revenu valuat project explicit
filgotinib revenu varieti indic indic includ rheumatoid
arthriti crohn diseas ulcer coliti ankylos spondyl psoriat
arthriti world-wide risk-adjust sale estim indic
follow ra uc
crohn remind galapago entitl portion ww
revenu filgotinib base agreement gilead galapago also entitl
receiv royalti base potenti futur sale cystic fibrosi
medic world-wide sale peak
respect galapago also entitl potenti
mileston partner varieti on-going program
econom galapago seri partnership differ term
signific agreement regard filgotinib profit share jv eu exclus
right benelux region potenti remain billion total potenti
mileston tier royalti rang payabl territori outsid
belgium franc germani itali luxembourg netherland spain unit
kingdom cf program transit note note
galapago still entitl singl digit low-teen percentag royalti cf sale
morphosi galapago split royalti novarti pay
tier royalti net sale low-teen low-twenti galapago entitl
royalti gilead sale full revenu ex-u sale
galapago entitl royalti gilead sale royalti
servier ex-u sale
cog project cog revenu cog remain
model product attribut compani galapago
oper expens project expens growth
stabil growth year thereaft sg expens grow compound-annual-growth-rate
risk price target includ phase studi could take signific time
phase ii safeti profil may assur protect unknown side-effect broader
phase program regulatori approv assur potenti
failur gain approv one geographi earlier-stag indic
ra market competit number market agent along agent
develop filgotinib pipelin product may encount unexpect
inform opinion research prepar co llc and/or and/or morgan
stanley mexico de bolsa de and/or canada limit use disclosur section includ morgan
stanley co llc mexico de bolsa de canada limit affili
necessari
import disclosur stock price chart equiti rate histori regard compani subject report pleas see morgan
stanley research disclosur websit www morganstanley com/researchdisclosur contact invest repres
research broadway attent research manag new york ny usa
valuat methodolog risk associ recommend rate price target referenc research report pleas contact client
support follow us/canada hong kong latin america london
singapor sydney tokyo altern may contact invest repres morgan
stanley research broadway attent research manag new york ny usa
follow analyst herebi certifi view compani secur discuss report accur express
receiv receiv direct indirect compens exchang express specif recommend view report matthew
unless otherwis state individu list cover page report research analyst
morgan stanley research publish accord conflict manag polici avail
www morganstanley com/institutional/research/conflictpolici portugues version polici found www morganstanley com br
import us regulatori disclosur subject compani
